Literature DB >> 16382457

Plasma total homocysteine and cardiovascular risk in patients submitted to liver transplantation.

Giampaolo Bianchi1, Francesco Nicolino, Giorgia Passerini, Gian Luca Grazi, Paola Zappoli, Romina Graziani, Annalisa Berzigotti, Raffaela Chianese, Vilma Mantovani, Antonio Daniele Pinna, Marco Zoli.   

Abstract

Patients submitted to orthotopic liver transplantation (OLT) show an increased rate of cardiovascular events. OLT subjects have high homocysteine (Hcy) levels, but no data are available on the association of Hcy with cardiovascular events. In a cross-sectional analysis, 230 subjects were studied at least 6 months after OLT (159 on cyclosporine, 71 on tacrolimus). Routine laboratory data and total Hcy were recorded, as well as the history of diabetes, hypertension, dyslipidemia, and overweight. Cardiovascular events occurring in a follow-up of 2-36 months were registered. OLT subjects had higher-than-normal Hcy (median 16.7 micromol/L, range 6.1-171.8) without difference between the 2 immunosuppressive agents. The prevalence of Hcy >15 micromol/L was also similar, and significantly correlated with creatinine levels. A total of 28 arterial events occurred in 25 patients during follow-up (11 in coronary arteries, 10 in peripheral arteries, and 7 in splanchnic arteries). Deep vein thromboses occurred in 2 patients, and splanchnic vein thromboses in 4 patients. Cardiovascular events were frequently associated to high Hcy and hypertension. Cox regression analysis showed that high Hcy was significantly associated with arterial events. The risk of any arterial event, coronary artery or peripheral artery event increased by nearly 10% for any increase in Hcy of 5 micromol/L. In conclusion, high Hcy may be involved in the pathogenesis of cardiovascular events in OLT patients. The usefulness of Hcy-lowering therapy remains to be verified. Copyright 2005 AASLD

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16382457     DOI: 10.1002/lt.20586

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  1 in total

1.  Hyperhomocysteinaemia and vascular disease in liver patients.

Authors:  G Bianchi; G Marchesini; M Zoli
Journal:  Gut       Date:  2006-06       Impact factor: 23.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.